BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32967636)

  • 1. GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: immunohistochemistry study showing the correlation between expression and survival.
    Achalandabaso Boira M; Di Martino M; Gordillo C; Adrados M; Martín-Pérez E
    BMC Cancer; 2020 Sep; 20(1):909. PubMed ID: 32967636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study.
    Du J; Gu J; Deng J; Kong L; Guo Y; Jin C; Bao Y; Fu D; Li J
    Cancer Invest; 2021 Oct; 39(9):741-755. PubMed ID: 34229540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.
    Takahashi M; Nojima H; Kuboki S; Horikoshi T; Yokota T; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
    Pancreatology; 2020 Sep; 20(6):1205-1212. PubMed ID: 32819845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.
    Chikamoto A; Inoue R; Komohara Y; Sakamaki K; Hashimoto D; Shiraishi S; Takamori H; Yamashita YI; Yoshida N; Yamanaka T; Yamashita Y; Baba H
    Ann Surg Oncol; 2017 Jul; 24(7):2040-2046. PubMed ID: 28180987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis.
    Sun HC; Qiu ZJ; Liu J; Sun J; Jiang T; Huang KJ; Yao M; Huang C
    Int J Oncol; 2007 Jun; 30(6):1359-67. PubMed ID: 17487356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
    Ann Surg Oncol; 2018 May; 25(5):1432-1439. PubMed ID: 29404819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis.
    Pizzi S; Porzionato A; Pasquali C; Guidolin D; Sperti C; Fogar P; Macchi V; De Caro R; Pedrazzoli S; Parenti A
    Histol Histopathol; 2009 Feb; 24(2):175-85. PubMed ID: 19085834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression and survival significance of sodium glucose transporters in pancreatic cancer.
    Du J; Gu J; Deng J; Kong L; Guo Y; Jin C; Bao Y; Fu D; Li J
    BMC Cancer; 2022 Jan; 22(1):116. PubMed ID: 35090421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
    Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
    Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
    BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
    PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.
    Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF
    Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas.
    Fujiwara S; Saiki Y; Ishizawa K; Fukushige S; Yamanaka M; Sato M; Ishida M; Motoi F; Unno M; Horii A
    Cancer Med; 2019 Apr; 8(4):1671-1678. PubMed ID: 30791220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.